Medtronic to promote Amgen's osteoporosis drug Prolia in US
This article was originally published in Clinica
Executive Summary
In what on the surface appears to be an odd move, medtech giant Medtronic has agreed to promote an osteoporosis drug, Amgen’s Prolia (denosumab), in the US. Financial terms of the deal, which will run for three years, were not disclosed.